Shield Therapeutics PLC logo

Shield Therapeutics PLC

£ 0.07 (0%) Jan 30
P/E:
At Loss
P/B:
0.45
Market Cap:
£ 38.36M ($ 47.20M)
Enterprise V:
£ 35.96M ($ 44.24M)
Volume:
245.42K
Avg Vol (2M):
3.08M
Also Trade In:
Volume:
245.42K
Market Cap £:
38.36M
Market Cap $:
47.20M
PE Ratio:
At Loss
Avg Vol (2-Month):
3.08M
Enterprise Value £:
35.96M
Enterprise Value $:
44.24M
PB Ratio:
0.45

Business Description

Description
Shield Therapeutics PLC is a specialty pharmaceutical company focused on the development and commercialization of late stage, hospital-focused pharmaceuticals which address areas of high unmet medical need. The company's operating segments which is based on key products include Feraccru, used as a novel oral treatment for iron deficiency anemia in patients, which is commercially available and PT20 used in treating hyperphosphatemia, which is in its last stage of completion. It generates maximum revenue from Feraccru segment.

Financial Strength

Name Current Vs Industry Vs History
Cash-To-Debt No Debt
Equity-to-Asset 0.91
Debt-to-EBITDA -0.01
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 2.41
Distress
Grey
Safe
Beneish M-Score 13.51
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 51.54
9-Day RSI 47.11
14-Day RSI 43.88
6-1 Month Momentum % 13.4
12-1 Month Momentum % -79.26

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 2.6
Quick Ratio 2.16
Cash Ratio 0.74
Days Inventory 375.96
Days Sales Outstanding 287.42
Days Payable 481.06

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -22.9